Owners, management and financials
CVR: 37053678
DKK 29,300,371
Gross profit
Net result: DKK -38,461,598
Y-mAbs Therapeutics, Inc. (100%)
CVR · view owners
Vincent Sainte-Catherine
Board: Antoine Bernasconi (chair) and 2 members
CVR · view management
Active
Founded 27 August 2015
CVR · view overview
13 employees
CVR · 2026
Director role ended: Michael Joseph Rossi
CVR · 29/09/2025
View the full event history
Y-mAbs Therapeutics A/S is a Danish company of the type Aktieselskab based in Hørsholm, founded in 2015. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Vincent Sainte-Catherine. The board consists of Antoine Bernasconi (chair), Julien Forest and Vincent Sainte-Catherine. The company is owned by Y-mAbs Therapeutics, Inc.. The company has 13 employees (2026). In 2025, the company reported a gross profit of DKK 29,300,371 and a net result of DKK -38,461,598 compared with DKK -12,500,464 the year before. Equity in the 2025 report amounted to DKK -163,651,844.
Source: annual report 2025, Danish Business Authority
Y-mAbs Therapeutics A/S is currently facing significant financial challenges, with consistent annual losses and negative equity. In 2025, the company reported a gross profit of 29.3 million DKK but incurred a loss of 38.5 million DKK, reflecting a declining trend in profitability compared to previous years. The gross profit peaked at 82.3 million DKK in 2022, but losses have escalated, leading to a concerning equity position of -163.7 million DKK. As a player in the research and experimental development sector, the company must address its profitability issues and improve its financial stability to strengthen its position in the industry.
AI-generated summary · Generated 16/08/2026
Virksomhedens formål er at udvikle lægemidler samen anden hermed forbunden virksomhed.
Source: annual reports filed with the Danish Business Authority.
| Period | Gross Profit | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 202501/01/2025 – 31/12/2025 | 29.3 mio. | -38.5 mio. | 15 mio. | -163.7 mio. | 53 | |
| 202401/01/2024 – 31/12/2024 | 74.3 mio. | -12.5 mio. | 26.5 mio. | -125.2 mio. | 56 | |
| 202301/01/2023 – 31/12/2023 | 70.7 mio. | -27.7 mio. | 56.7 mio. | -112.7 mio. | 59 | |
| 202201/01/2022 – 31/12/2022 | 82.3 mio. | -85.7 mio. | 22.9 mio. | -84.9 mio. | 101 | |
| 202101/01/2021 – 31/12/2021 | 67.5 mio. | -42.1 mio. | 61.5 mio. | -39.3 mio. | 88 | |
| 202001/01/2020 – 31/12/2020 | 82.4 mio. | -1.2 mio. | 52 mio. | 2.8 mio. | 62 | |
| 201901/01/2019 – 31/12/2019 | 52 mio. | -2.6 mio. | 35.7 mio. | 4 mio. | 36 | |
| 201801/01/2018 – 31/12/2018 | 28.6 mio. | -4.2 mio. | 17.2 mio. | 1.6 mio. | 19 | |
| 201701/01/2017 – 31/12/2017 | 13.2 mio. | -2.2 mio. | 10.9 mio. | 808 t. | - |
Compared to 1.039 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
Screen owners and management against the Danish FSA's official PEP lists
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationThe CVR number of Y-mAbs Therapeutics A/S is 37053678.
Y-mAbs Therapeutics A/S is owned by Y-mAbs Therapeutics, Inc..
The management of Y-mAbs Therapeutics A/S consists of Vincent Sainte-Catherine.
The board of Y-mAbs Therapeutics A/S consists of Antoine Bernasconi, Julien Forest and Vincent Sainte-Catherine, with Antoine Bernasconi as chair.
In 2025, Y-mAbs Therapeutics A/S reported a gross profit of DKK 29,300,371.
Y-mAbs Therapeutics A/S had 13 employees in 2026 according to the Danish CVR register.
Claim this page to add your logo and social links. Free to get started.
Y-mAbs Therapeutics A/S has published its annual report for 2025. Gross profit came to DKK 29,300,371, and the net result was DKK -38,461,598.
Address changed to Agern Alle 13 13, 2970 Hørsholm (January 29, 2026).
As of December 29, 2025, EY Godkendt Revisionspartnerselskab has been appointed auditor of Y-mAbs Therapeutics A/S.
As of December 29, 2025, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Antoine Bernasconi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Vincent Sainte-Catherine has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Julien Forest has joined the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Michael Joseph Rossi has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Peter Paul Pfreundschuh has left the board of directors of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Vincent Sainte-Catherine is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of September 29, 2025, Michael Joseph Rossi has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2024. Gross profit came to DKK 74,262,634, and the net result was DKK -12,500,464.
As of May 28, 2025, Peter Paul Pfreundschuh has joined the board of directors of Y-mAbs Therapeutics A/S.
As of July 31, 2024, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of July 31, 2024, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
As of July 30, 2024, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2023. Gross profit came to DKK 70,656,043, and the net result was DKK -27,748,840.
As of November 29, 2023, Michael Joseph Rossi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Michael Joseph Rossi is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of November 28, 2023, Thomas Gad has stepped down as adm. dir. of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2022. Gross profit came to DKK 82,332,358, and the net result was DKK -85,685,825.
Y-mAbs Therapeutics A/S has published its annual report for 2021. Gross profit came to DKK 67,549,569, and the net result was DKK -42,087,769.
As of May 12, 2022, Johan Ernst Wedell-Wedellsborg has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Claus Juan Møller-San Pedro has left the board of directors of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Thomas Gad is registered as adm. dir. of Y-mAbs Therapeutics A/S.
As of May 12, 2022, Claus Juan Møller-San Pedro has stepped down as director of Y-mAbs Therapeutics A/S.
As of May 11, 2022, Thomas Gad has left the board of directors of Y-mAbs Therapeutics A/S.
As of May 11, 2022, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Johan Ernst Wedell-Wedellsborg has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Ashutosh Tyagi has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, David Neil Gill has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Jim Irvin Healy has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Gérard Ber has left the board of directors of Y-mAbs Therapeutics A/S.
As of October 28, 2021, Laura J. Hamill has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2020. Gross profit came to DKK 82,433,523, and the net result was DKK -1,202,417.
As of June 11, 2020, Laura J. Hamill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of June 11, 2020, Gregory Stephen Raskin has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2019. Gross profit came to DKK 52,032,447, and the net result was DKK -2,579,400.
As of December 20, 2019, Bo Kruse has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2018. Gross profit came to DKK 28,598,680, and the net result was DKK -4,193,681.
As of December 18, 2018, Gérard Ber has joined the board of directors of Y-mAbs Therapeutics A/S.
As of December 18, 2018, Michael Joachim Buschle has left the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its annual report for 2017. Gross profit came to DKK 13,194,221, and the net result was DKK -2,177,894.
As of January 18, 2018, Ashutosh Tyagi has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, David Neil Gill has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Michael Joachim Buschle has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 18, 2018, Jim Irvin Healy has joined the board of directors of Y-mAbs Therapeutics A/S.
Y-mAbs Therapeutics A/S has published its interim report for the period August 27, 2015 – December 31, 2016.
As of January 20, 2016, Johan Ernst Wedell-Wedellsborg has joined the board of directors of Y-mAbs Therapeutics A/S.
As of January 20, 2016, Gregory Stephen Raskin has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Claus Juan Møller-San Pedro has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Thomas Gad has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Bo Kruse has joined the board of directors of Y-mAbs Therapeutics A/S.
As of August 27, 2015, Claus Juan Møller-San Pedro is registered as director of Y-mAbs Therapeutics A/S.
As of August 27, 2015, is registered as an owner of Y-mAbs Therapeutics A/S with an ownership share of 100%.
Y-mAbs Therapeutics A/S was founded on August 27, 2015.
Companies in the same industry and area
CVR 37726028
CVR 29217939
CVR 31762863
CVR 28512457
CVR 27408753
